GPBP1L1 Inhibitors
GPBP1L1 Inhibitors encompass a series of chemical compounds that mitigate the functional activity of GPBP1L1, a protein associated with microtubule dynamics and cellular structure maintenance, through various signaling pathways. For instance, PD 98059 and SB 203580 operate by inhibiting the MEK/ERK and p38 MAPK pathways, respectively, pathways which, when suppressed, can lead to a reduction in GPBP1L1 activity if GPBP1L1 is dependent on these pathways for stabilization or stress response functions. Additionally, the PI3K/AKT pathway, which is closely tied to cytoskeletal organization, can be targeted by LY 294002 to downregulate activities potentially linked to GPBP1L1. Similarly, Y-27632 and ML-7, by selectively inhibiting ROCK and MLCK, disrupt the phosphorylation of downstream targets and activation of myosin light chains, respectively, which could be crucial for GPBP1L1's role in cytoskeletal dynamics and cell morphology.
Further indirect inhibition of GPBP1L1 is achieved through the modulation of cellular structures and the cytoskeleton itself. Brefeldin A, by disassembling the Golgi apparatus, may affect GPBP1L1 localization or activity within this cellular compartment. Microtubule targeting agents such as colchicine and nocodazole destabilize the microtubule network, potentially diminishing GPBP1L1's interaction with or reliance on microtubules. In contrast, taxol stabilizes microtubules, which could inadvertently inhibit GPBP1L1 by preventing the dynamic interactions required for its function. The activity of GPBP1L1 may also be indirectly decreased by Gö 6983, a pan-PKC inhibitor, which alters signaling pathways that GPBP1L1 might rely on for its structural or motility-related functions. Lastly, Lithium Chloride, by inhibiting GSK-3, could lead to the destabilization of cellular components or signaling pathways that are necessary for GPBP1L1's functionality within the cell. Collectively, these inhibitors demonstrate the potential to indirectly attenuate GPBP1L1's functional role through diverse impacts on cellular signaling and structural integrity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of the MEK/ERK pathway. By blocking MEK activation, it indirectly inhibits GPBP1L1, which is associated with microtubule dynamics and cellular structure maintenance. Inhibition of this pathway can lead to reduced GPBP1L1 function as it may rely on MEK/ERK signaling for its stabilization or localization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of PI3K, leading to the downregulation of the PI3K/AKT pathway. Since GPBP1L1 has been implicated in pathways involving cytoskeletal organization, the inhibition of PI3K could diminish GPBP1L1 activity by disrupting its associated signaling networks. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK, which is part of the Rho-associated kinase pathway involved in cell shape and motility. As GPBP1L1 is connected to the cytoskeleton, inhibiting ROCK may impair GPBP1L1's role in cytoskeletal dynamics by preventing the phosphorylation of downstream targets that could interact with GPBP1L1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK, a protein that responds to stress stimuli. If GPBP1L1 functions are modulated by stress responses involving p38 MAPK, then SB 203580 would indirectly inhibit GPBP1L1 by dampening the stress-activated signaling pathway it may be involved in. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus. Given that GPBP1L1 is involved in cellular structural integrity, the disassembly of the Golgi complex can indirectly lead to a decrease in GPBP1L1 function by affecting the cellular compartments where GPBP1L1 might be active or localized. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin is an inhibitor of myosin II ATPase activity, which is crucial for muscle contraction and cell motility. If GPBP1L1 interacts with or depends on myosin II for its function, its activity could be diminished by the disruption of myosin-based processes, potentially altering GPBP1L1's role in cell structure and dynamics. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, inhibiting microtubule polymerization. Since GPBP1L1 may interact with microtubules, colchicine would lead to a functional inhibition of GPBP1L1 by destabilizing the microtubule network that GPBP1L1 might be associated with, thereby affecting its stability or localization within the cell. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is another microtubule-depolymerizing agent. It can indirectly inhibit GPBP1L1 by disrupting the microtubule framework that is essential for the proper function or distribution of GPBP1L1 within the cell, assuming GPBP1L1 is associated with microtubules or microtubule-dependent processes. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol stabilizes microtubules, preventing their disassembly. This could indirectly inhibit GPBP1L1 if it requires dynamic microtubules for its activity; stabilized microtubules might hinder GPBP1L1's ability to interact with or modify the cytoskeleton in its functional role. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), impacting cell contraction and shape. If GPBP1L1 is involved in pathways that regulate cell shape through myosin light chains, then ML-7 could diminish GPBP1L1 function by preventing the phosphorylation and activation of myosin light chains. | ||||||